SCIENTIFIC
TEAM DEVELOPMENT • SCIENTIFIC ADVISORY
Worked with major pharmaceutical company keen to expand its portfolio and expand into niche orphan indications.
A thorough review of the opportunities and risks associated with the potential new indication was prepared and presented to the client for board-level decision-making. As a result of the review the pharma company decided not to purse the opportunity.
